Navigation Links
Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed Todd Lorenz, M.D., as the company's Chief Medical Officer. Dr. Lorenz's career encompasses nearly 20 years of experience focused on the clinical development of novel medicines.

"We are excited to welcome Dr. Lorenz to the Catalyst team," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Hiring an experienced CMO to lead our development efforts is a critical step as Catalyst expands from drug discovery into clinical development. His expertise in clinical development and operations is particularly welcome as we advance our lead program, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, toward an IND filing in 2009."

"I am delighted to join Catalyst and have the opportunity to shape the clinical strategy for the company's pipeline of protease therapeutics," said Dr. Lorenz. "CB 813 is a highly promising compound with the potential to become a best-in-class therapeutic for hemophilia patients. Catalyst's protease therapeutics platform is poised to deliver a new class of biologics comparable in depth and scope to monoclonal antibodies."

Throughout his career, Dr. Lorenz has held leadership positions in the biotechnology and pharmaceutical industry with responsibilities across several therapeutic areas. Dr. Lorenz joins Catalyst from Johnson & Johnson (J&J), where he was Vice President and Associate Therapeutic Head for Cardiovascular Development. In this role, he contributed to clinical development efforts in several internal J&J entities including Scios, the Corporate Office of Science and Technology and Peninsula Pharmaceuticals. Dr. Lorenz served as Chief Medical Officer for Orexigen Therapeutics from 2005-2006 and was Chief Medical Officer at Corgentech from 2001-2005 where he was responsible for the clinical development of a transcription factor inhibitor through Phase 3 clinical development. From 1994-2001 at COR Therapeutics, Dr. Lorenz was intimately involved in the development, approval and medical affairs support for Integrilin(R), a novel platelet inhibitor, and from 1990-1994 he focused on the development of immunology product candidates at XOMA.

Dr. Lorenz is a graduate of Case Western Reserve University School of Medicine and trained in Internal Medicine at the University of Texas Southwestern. He completed a fellowship in Endocrinology and Metabolism at the University of California, San Francisco, and is board certified in both subspecialties. Dr. Lorenz has published extensively in journals such as Journal of the American Medical Association (JAMA), The Lancet, Circulation and the Annals of Thoracic Surgery.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Initially, Catalyst is focusing its product development efforts on drug candidates for hemophilia, age-related macular degeneration, oncology and inflammation. To date, Catalyst has established two discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit

Catalyst Biosciences, Inc.

Erik Wiberg

Chief Financial Officer


BCC Partners for Catalyst Biosciences, Inc.

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662

SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Cambridge, MA (PRWEB) , ... December 01, 2015 , ... ... 2013, in part due to decreases in utilization of hospital and nonhospital care, according ... report, CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
Breaking Medicine Technology: